Neovasc to Present Corporate Overview at the 8th Annual SVB Leerink Global Healthcare Conference
NASDAQ, TSX: NVCN
VANCOUVER, Feb. 27, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN) (TSX:NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that Fred Colen, Chief Executive Officer, will present a corporate overview at the 8th Annual SVB Leerink Global Healthcare Conference, being held in New York, NY on February 27 – March 1, 2019.
Neovasc Presentation Details |
|
Date: |
Friday, March 1 |
Time: |
9:00am Eastern Time |
Webcast: |
|
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Reducer, for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States , Canada and Europe . For more information, visit: www.neovasc.com.
SOURCE Neovasc Inc.
Chris Clark, Chief Financial Officer, Neovasc Inc., 604 248-4138, [email protected]; Jeremy Feffer, LifeSci Advisors, LLC, 212-915-2568
Share this article